xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

663

PATEL et al.

rhinosinusitis patients after endoscopic sinus surgery. Eur Arch Otorhinolaryngol . 2019;276:1397–1403. 1407. Harvey RJ, Snidvongs K, Kalish LH, Oakley GM, Sacks R. Corticosteroid nasal irrigations are more effective than sim ple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol . 2018;8:461–470. 1408. Rawal RB, Deal AM, Ebert CS Jr, et al. Post-operative budes onide irrigations for patients with polyposis: a blinded, ran domized controlled trial. Rhinology . 2015;53:227–234. 1409. Sindwani R, Han JK, Soteres DF, et al. NAVIGATE I: ran domized, placebo-controlled, double-blind trial of the exhala tion delivery system with fluticasone for chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy . 2019;33:69–82. 1410. Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: Random ized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol . 2019;143:126–134.e5 1411. Kobayashi Y, Yasuba H, Asako M, et al. HFA-BDP metered dose inhaler exhaled through the nose improves eosinophilic chronic rhinosinusitis with bronchial asthma: a blinded, placebo-controlled study. Front Immunol . 2018;9:2192. 1412. Soteres DF, Messina J Jr, Carothers J, Mahmoud R, Djupesland PG. Navigate I: A randomized double-blind trial of a fluticasone propionate exhalation delivery system (FLU-EDS) for treatment of chronic rhinosinusitis with nasal polyps (CRSWNP). J Allergy Clin Immunol . 2017;139:AB66 1413. Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol . 2018;8:471– 481. 1414. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol . 2011;128: 989-995.e1 8. 1415. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effec tive in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol . 2013;131:110–116.e1. 1416. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology . 2010;48:318– 324. 1417. Stryjewska-Makuch G, Humeniuk-Arasiewicz M, Jura-Szołtys E, Glück J. The effect of antileukotrienes on the results of postoperative treatment of paranasal sinuses in patients with non-steroidal anti-inflammatory drug-exacerbated res piratory disease. Int Arch Allergy Immunol . 2019;179:281– 289. 1418. Van Gerven L, Steelant B, Hellings PW. Nasal hyperreactiv ity in rhinitis: A diagnostic and therapeutic challenge. Allergy . 2018;73:1784–1791. 1419. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med . 1998;157(4 pt 1): 1187–1194. 1420. Larivée N, Chin CJ. Aspirin desensitization therapy in aspirin exacerbated respiratory disease: a systematic review. Int Forum Allergy Rhinol . 2020;10:450–464.

1421. Świerczyńska-Krępa M, Sanak M, Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin tolerant asthma: A double-blind study. J Allergy Clin Immunol . 2014;134:883–890. 1422. Fruth K, Pogorzelski B, Schmidtmann I, et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy . 2013;68:659–665. 1423. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol . 2007;119:157–164. 1424. Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal out comes of aspirin desensitization in aspirin exacerbated respi ratory disease. Otolaryngol Head Neck Surg . 2014;151:575–581. 1425. Liu YF, Richardson CM, Bernard SH, Church CA, Seiberling KA. Antibiotics, steroids, and combination therapy in chronic rhinosinusitis without nasal polyps in adults. Ear Nose Throat J . 2018;97:167–172. 1426. Ikeda K, Sakurada T, Suzaki Y, Takasaka T. Efficacy of sys temic corticosteroid treatment for anosmia with nasal and paranasal sinus disease. Rhinology . 1995;33:162–165. 1427. Zeng M, Long XB, Cui YH, Liu Z. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. Am J Rhinol Allergy . 2011;25:e203–e207. 1428. Hansen FS, Djupesland PG, Fokkens WJ. Preliminary effi cacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis. Rhinology . 2010;48:292–299. 1429. Lund VJ, Black JH, Szabó LZ, Schrewelius C, Åkerlund A. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology . 2004;42:57–62. 1430. Deng J, Chen F, Lai YY, et al. Lack of additional effects of long-term, low-dose clarithromycin combined treatment com pared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial. Int Forum Allergy Rhi nol . 2018;8:8–14. 1431. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryn goscope . 2006;116:189–193. 1432. Guilemany JM, García-Piñero A, Alobid I, et al. The loss of smell in persistent allergic rhinitis is improved by levoceti rizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). Int Arch Allergy Immunol . 2012;158:184–190. 1433. Kalpaklioglu AF, Kavut AB. Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis. Am J Rhinol Allergy . 2010;24:29–33. 1434. Wober W, Crespo CD, Bähre M. Evaluation of the drug mon itoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age. Arzneimittelforschung . 1997;47:841–844. 1435. Gambardella R. A comparison of the efficacy of azelastine nasal spray and loratidine tablets in the treatment of seasonal allergic rhinitis. J Int Med Res . 1993;21:268–275. 1436. Higaki T, Okano M, Makihara S, et al. Early interventional treatment with intranasal corticosteroids compared with pos tonset treatment in pollinosis. Ann Allergy Asthma Immunol . 2012;109:458–464.